Mitsubishi UFJ Asset Management Co. Ltd. Makes New $2.83 Million Investment in Twist Bioscience Corporation $TWST

Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 27,485 shares of the company’s stock, valued at approximately $2,828,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TWST. Quarry LP bought a new stake in Twist Bioscience in the 3rd quarter valued at $28,000. Western Wealth Management LLC acquired a new stake in Twist Bioscience in the 1st quarter worth about $31,000. Strs Ohio acquired a new stake in shares of Twist Bioscience in the first quarter valued at approximately $33,000. Strategic Advocates LLC lifted its position in shares of Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after acquiring an additional 906 shares during the period. Finally, SBI Securities Co. Ltd. lifted its position in Twist Bioscience by 68.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after purchasing an additional 571 shares during the period.

Insider Activity

In other news, SVP Paula Green sold 291 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the sale, the senior vice president directly owned 120,414 shares of the company’s stock, valued at $10,514,550.48. This trade represents a 0.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,399 shares of Twist Bioscience stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the sale, the chief financial officer directly owned 110,276 shares in the company, valued at approximately $10,402,335.08. This represents a 2.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 151,529 shares of company stock worth $17,708,772. Corporate insiders own 3.08% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Piper Sandler upped their target price on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Robert W. Baird upped their price target on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Barclays upped their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. Finally, Guggenheim raised their target price on Twist Bioscience from $60.00 to $107.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $98.30.

Twist Bioscience Trading Up 6.8%

NASDAQ:TWST opened at $145.59 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The firm has a 50-day moving average of $100.69 and a 200-day moving average of $70.33. The company has a market cap of $9.13 billion, a PE ratio of -65.58 and a beta of 2.14. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $145.93.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period last year, the company earned $0.33 earnings per share. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.